QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quik, M. Articles by Whiteaker, P. Search for Related Content PubMed PubMed Citation Articles by Quik, M. Articles by Whiteaker, P.

L-DOPA Treatment Modulates Nicotinic Receptors in Monkey Striatum

The Parkinson's Institute, Sunnyvale, California (M.Q., T.B., M.O.); Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado (P.W., M.J.M.); Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland (H.F.); and Department of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M.)

Nicotinic acetylcholine receptor (nAChR) activation is well known to stimulate dopamine release in the striatum. This phenomenon may be physiologically significant in the control of motor function, as well as in pathological conditions such as Parkinson's disease. An understanding of the mechanisms that influence nAChR expression and function is therefore important. Because the dopamine precursor L-DOPA is the most commonly used therapeutic agent for Parkinson's disease, we investigated the effects of L-DOPA treatment on striatal nAChR expression in unlesioned and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned monkeys. In unlesioned animals, L-DOPA (15 mg/kg) administered twice daily for 2 weeks decreased both ¹²⁵I-epibatidine and [¹²⁵I]iodo-3-[2(S)-azetidinylmethoxy]pyridine (A-85380) binding sites in the caudate and putamen, but did not affect ¹²⁵I--CtxMII sites. -CtxMII inhibition of striatal ¹²⁵I-epibatidine and [¹²⁵I]A-85380 binding with -CtxMII suggest that there are both high- (K_i < 0.2 nM) and low-affinity (K_i > 100 nM) -CtxMII-sensitive sites, as well as -CtxMII-resistant sites, and that L-DOPA treatment influences only the low-affinity -CtxMII-sensitive subtype. The L-DOPA effect was selective for striatal nAChRs with no change in cortical sites. Monkeys with severe nigrostriatal damage did not exhibit L-DOPA-induced declines in striatal nAChRs, suggesting that L-DOPA primarily affects nAChRs associated with dopaminergic terminals. In summary, these data show that L-DOPA treatment decreases nAChR expression, in contrast with the well established up-regulation of these sites by chronic nicotine exposure. Furthermore, they demonstrate preferential L-DOPA regulation of a novel low-affinity -CtxMII-sensitive site. These declines in nAChRs with L-DOPA may be relevant to both the therapeutic and side effect profiles of L-DOPA therapy in Parkinson's disease.

Address correspondence to: Dr. Maryka Quik, The Parkinson's Institute, 1170 Morse Ave., Sunnyvale, CA 94089-1605. E-mail: mquik{at}thepi.org

This article has been cited by other articles:

				X. A. Perez, T. Bordia, J. M. McIntosh, S. R. Grady, and M. Quik Long-Term Nicotine Treatment Differentially Regulates Striatal {alpha}6{alpha}4{beta}2* and {alpha}6(Non{alpha}4){beta}2* nAChR Expression and Function Mol. Pharmacol., September 1, 2008; 74(3): 844 - 853. [Abstract] [Full Text] [PDF]

				T. Bordia, N. Parameswaran, H. Fan, J. W. Langston, J. M. McIntosh, and M. Quik Partial Recovery of Striatal Nicotinic Receptors in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Monkeys with Chronic Oral Nicotine J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 285 - 292. [Abstract] [Full Text] [PDF]

				M. Quik, S. Vailati, T. Bordia, J. M. Kulak, H. Fan, J. M. McIntosh, F. Clementi, and C. Gotti Subunit Composition of Nicotinic Receptors in Monkey Striatum: Effect of Treatments with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA Mol. Pharmacol., January 1, 2005; 67(1): 32 - 41. [Abstract] [Full Text] [PDF]